vida: extract claims from 2026-04-23-glp1-substance-use-disorder-33-trials

- Source: inbox/queue/2026-04-23-glp1-substance-use-disorder-33-trials.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -32,3 +32,10 @@ WHO's conditional recommendation acknowledges 'limited long-term evidence' and '
 **Source:** Frontiers in Clinical Diabetes and Healthcare 2025 review
 
 Exercise helps preserve muscle mass and sustain weight loss after GLP-1 cessation. The review states that stopping GLP-1 therapy alone leads to weight regain, but exercise provides a partial mitigation pathway. Future obesity management will likely prioritize integrated approaches (pharmacotherapy + lifestyle) rather than pharmacotherapy replacing lifestyle.
+
+
+## Extending Evidence
+
+**Source:** PubMed 41696398 systematic review, 33 SUD trials
+
+The continuous treatment requirement extends beyond metabolic conditions to substance use disorders. The same mesolimbic dopamine circuits that mediate hedonic eating also underlie addiction, suggesting GLP-1s would require chronic administration for SUD just as they do for obesity. This creates a parallel chronic-use economic model for an entirely new therapeutic category.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The same VTA dopamine mechanism underlying GLP-1 effects on hedonic eating extends to addiction pathways creating a potential pharmacological common denominator for reward dysregulation conditions
+confidence: experimental
+source: PubMed 41696398 systematic review, Qeadan et al. Addiction 2025, Harvard Gazette 2026
+created: 2026-04-23
+title: GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
+agent: vida
+sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
+scope: causal
+sourcer: PubMed/ClinicalTrials.gov systematic review
+challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+---
+
+# GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
+
+A systematic review of ClinicalTrials.gov identified 33 registered trials examining GLP-1 receptor agonists for substance use disorders: 15 for alcohol use disorder, 9 for nicotine/tobacco, 4 for cocaine, 4 for opioid use disorder, and 1 for methamphetamine. The mechanistic basis is shared with obesity treatment: GLP-1 receptors are expressed in the mesolimbic dopamine system (VTA, nucleus accumbens, amygdala) that underlies both hedonic eating and substance addiction. Early clinical evidence supports this mechanism: an RCT showed low-dose semaglutide reduced laboratory alcohol self-administration, drinks per drinking day, and craving in people with AUD. Real-world analysis by Qeadan et al. found that among people with pre-existing SUD, GLP-1 users showed fewer ER visits, hospitalizations, and deaths related to substance use. Animal studies demonstrate GLP-1s lower self-administration of opioids (heroin, fentanyl, oxycodone) and reduce relapse-like behavior. The breadth of the trial pipeline—with semaglutide as the most studied agent (n=15 trials)—indicates this is being taken seriously as a paradigm shift for addiction medicine. However, most OUD data remains in animal models, and human trial results are not yet published. The field is 2-3 years from definitive clinical evidence, making this experimental rather than proven.

inbox/archive/health/2026-04-23-glp1-substance-use-disorder-33-trials.md

@@ -7,9 +7,12 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: systematic review + news synthesis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: high
 tags: [glp-1, addiction, SUD, alcohol-use-disorder, opioid-use-disorder, substance-use, clinical-trials, dopamine, reward-circuitry, semaglutide]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content